Clinical Trial Update: The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis

View source ↗

Summary

This update examines the role of CD4+ T cell subsets in Vedolizumab’s mechanism of action in ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)

Snippet

Sponsor: University of British Columbia | Conditions: Ulcerative Colitis | Status: ACTIVE_NOT_RECRUITING